In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sage Therapeutics, Inc.

Latest From Sage Therapeutics, Inc.

Sage Details 40% Job Cuts While Zurzuvae’s Future In MDD Remains Unclear

Zurzuvae will launch this year for postpartum depression, but US FDA rejection of the drug in major depressive disorder spurred Sage to cut R&D programs and jobs as it and partner Biogen evaluate next steps in MDD.

Business Strategies Restructuring

Finance Watch: Sage Warns Of Job Cuts, Joins Peers Making Cash Last After Setbacks

Public Company Edition: Sage will reveal cost reductions later in the third quarter after the US FDA approved zuranolone for the smaller of two depression indications. Also, Karyopharm revealed a 20% workforce reduction, Harmony accessed up to $185m in debt and Astellas invested $50m in Poseida.

Financing Restructuring

Reprioritization On Cards After Sage/Biogen’s Zurzuvae Receives CRL For MDD

The firms’ Zurzuvae has become the first oral drug to win US approval for postpartum depression but a thumbs down in the larger major depressive disorder indication has raised concerns that Biogen could pull out of the partnership as Sage turns its efforts to cutting costs.

Complete Response Letters Neurology

After CRL In MDD, Sage/Biogen’s Zuranolone Would Need More Effectiveness Data

Zurzuvae becomes first oral drug for postpartum depression but will need at least one additional study to enter larger major depressive disorder market after US FDA cites a lack of effectiveness. Continued MDD development in doubt with both Sage and partner Biogen in cost-cutting frame.

Complete Response Letters Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET